To enable Guardant Health to lead the disruption of cancer treatments through non-invasive cancer screening, the Technology Development Team is seeking a highly motivated Research Associate to help develop, test, and improve sample preparation technologies for rare variant and epigenetic studies with next-generation sequencing. At Guardant, we leverage the most advanced technologies and work with leaders in many different fields to create the most impactful and meaningful technologies for cancer management.

As a Research Associate supporting product and technology development, you will work with members within the team and interface with multiple teams including process engineering, clinical operations, research operations, and bioinformatics. You will be hands on in the lab and be required to design, implement, and validate new technologies related to liquid biopsy sequencing assays for the early detection, treatment, and monitoring of all cancer types.

RESPONSIBILITIES

• Operate next generation sequencing instruments
• Run sequencing sample preparation assays in medium to high throughput environment
• Test and improve new sequencing sample preparation assays
• Log and track research samples throughout sequencing workflow
• Maintain appropriate inventory of lab supplies
• Bring a can do attitude to solve new and challenging problems in a high pace environment
• Analyze data and troubleshoot issues within the tech dev team and among other teams
• Collaborate with all functions within project teams
• Engage in early design of products and perform experiments both independently and under the supervision of Senior team members within Tech Dev and Bioinformatics groups
• Be able to present updates, write reports and SOPs, and contribute to technical discussions

ABOUT YOU

• The ability to handle biological samples (i.e. tissue, biofluid, etc.) is a must
• Excellent written and oral communication skills is a must
• Professional hands-on experience in industrial setting in genomics field is a plus (operational experience is preferred)
• Hands-on experience in running sequencing platforms and assays is a plus

Guardant Health develops breakthrough diagnostic technologies to improve cancer management. With Guardant360, we offer real-time, biopsy-free tumor sequencing that tracks tumor genomics in real-time and identifies associated treatment options. The recent introduction of groundbreaking analytical tools, including our Tumor Response Map and a mobile-enabled physician portal, further advance Guardant Health’s momentum.

Guardant Health has raised almost $200M from OrbiMed, Sequoia Capital, Khosla Ventures, Lightspeed Venture Partners, and Formation8, and is led by a seasoned management team of thought leaders and successful serial entrepreneurs in next generation sequencing and rare cell diagnostics. They are advised by an oncologist-led medical steering committee from leading cancer centers.